MX2024015644A - Formas en estado solido de n-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-6-morfolino-quinolina-4-carboxamida - Google Patents

Formas en estado solido de n-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-6-morfolino-quinolina-4-carboxamida

Info

Publication number
MX2024015644A
MX2024015644A MX2024015644A MX2024015644A MX2024015644A MX 2024015644 A MX2024015644 A MX 2024015644A MX 2024015644 A MX2024015644 A MX 2024015644A MX 2024015644 A MX2024015644 A MX 2024015644A MX 2024015644 A MX2024015644 A MX 2024015644A
Authority
MX
Mexico
Prior art keywords
cyanothiazolidin
morpholinoquinoline
oxoethyl
carboxamide
solid
Prior art date
Application number
MX2024015644A
Other languages
English (en)
Inventor
Yvonne Sawyer
Anna Ardané
Staffan Karlsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2024015644A publication Critical patent/MX2024015644A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Formas en estado sólido de N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-6-morfolinoquinolina-4-carboxamida; composiciones farmacéuticas correspondientes; usos para tratar o prevenir afecciones mediadas por la proteína activadora de fibroblastos prolil endopeptidasa (FAP); kits; y métodos de preparación.
MX2024015644A 2022-06-21 2024-12-16 Formas en estado solido de n-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-6-morfolino-quinolina-4-carboxamida MX2024015644A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263366696P 2022-06-21 2022-06-21
PCT/EP2023/066559 WO2023247487A1 (en) 2022-06-21 2023-06-20 Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide

Publications (1)

Publication Number Publication Date
MX2024015644A true MX2024015644A (es) 2025-02-10

Family

ID=87047690

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024015644A MX2024015644A (es) 2022-06-21 2024-12-16 Formas en estado solido de n-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-6-morfolino-quinolina-4-carboxamida

Country Status (12)

Country Link
US (1) US20250368637A1 (es)
EP (1) EP4543877A1 (es)
JP (1) JP2025521304A (es)
KR (1) KR20250027736A (es)
CN (2) CN120554349A (es)
AU (1) AU2023288645A1 (es)
CA (1) CA3260370A1 (es)
CL (1) CL2024003894A1 (es)
IL (1) IL317722A (es)
MA (1) MA71234A (es)
MX (1) MX2024015644A (es)
WO (1) WO2023247487A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026119802A1 (en) 2024-12-02 2026-06-11 Astrazeneca Ab Dosing regimen for the treatment of fap-mediated conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
CN113811529A (zh) * 2018-12-21 2021-12-17 普拉西斯生物技术有限责任公司 成纤维细胞激活蛋白抑制剂
UY39569A (es) * 2020-12-17 2022-07-29 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas

Also Published As

Publication number Publication date
WO2023247487A1 (en) 2023-12-28
US20250368637A1 (en) 2025-12-04
EP4543877A1 (en) 2025-04-30
JP2025521304A (ja) 2025-07-08
IL317722A (en) 2025-02-01
KR20250027736A (ko) 2025-02-27
MA71234A (fr) 2025-04-30
CN120554349A (zh) 2025-08-29
CN119585266A (zh) 2025-03-07
AU2023288645A1 (en) 2025-02-13
CA3260370A1 (en) 2023-12-28
CL2024003894A1 (es) 2025-02-07

Similar Documents

Publication Publication Date Title
CR20230314A (es) N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas
EA201000920A1 (ru) Ингибиторы пролилгидроксилазы
AR043795A1 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
BR112022024128A2 (pt) Composição de microbiota vaginal, e, método para tratar uma infecção
TR200002940T2 (tr) Parazitlerin sebep olduğu hastalıkların papain süperfamilyasından sistein proteazların inhibisyonu yoluyla tedavisi
EA200600588A1 (ru) Соединения, содержащие галоидалкил, как ингибиторы цистеиновых протеаз
MX2024003107A (es) Agonistas de ahr.
JOP20220193A1 (ar) صياغات من الأجسام المضادة لـ tslp البشرية وطرق لاستخدامها
JOP20220353A1 (ar) آلية إطلاق عطر، وطريقة لها واستخداماتها
WO2021191689A3 (en) Treatment of inflammatory diseases with peptides and pharmaceutical compositions
MX2021015324A (es) Inhibidores heteroaromaticos de las proteinasas de astacina.
EP4126913A4 (en) INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS OF HOST CELLS AND FORMULATIONS FOR THE TREATMENT OF COVID-19
MX2023012672A (es) Nuevo anticuerpo anti-vista estable.
CL2024003894A1 (es) Formas en estado sólido de n-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-6-morfolino-quinolina-4-carboxamida
MX2025005954A (es) Composicion del conjugado anticuerpo anti-her3-farmaco y uso farmaceutico de la misma
JOP20230034A1 (ar) مثبطات إفراز البروتين
MA65143A1 (fr) Compositions d'inhibiteur de transporteur dépendant du sodium apical
MX2024007301A (es) Peptidos y metodos para usar en el tratamiento del dolor.
Han et al. Rho-associated kinase inhibitor enhances the culture condition of isolated mouse salivary gland cells in vitro
MX2025004871A (es) Derivados de fenilbencensulfonamida sustituidos y usos de estos
MX2009003563A (es) Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina.
JOP20240149A1 (ar) مثبطات bcl-2 (الخلية ب لمفومة 2)
MX2007011739A (es) Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa.
MX2024015642A (es) N-(2-(3-ciano-2-azabiciclo[3.1.0]hexan-2-il)-2-oxoetil)-quinolina-4-carboxamidas
MX2024009257A (es) Composiciones y metodos para inhibir la expresion de la proteina precalicreina (pkk).